ストックスクリーナーアプリを入手
8.28
3.38%
-0.29
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely - Yahoo Finance
(YMAB) Trading Signals - Stock Traders Daily
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Australia
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Buy” by Brokerages - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Buy” Rating from HC Wainwright - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives "Buy" Rating from HC Wainwright - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Equities Analysts Offer Predictions for YMAB FY2024 Earnings - MarketBeat
Brookline Capital Management Predicts YMAB FY2024 Earnings - Defense World
Intech Investment Management LLC Invests $133,000 in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Trend Tracker for (YMAB) - Stock Traders Daily
Y-mAbs' CD38-SADA Shows Promising Anti-Tumor Results in NHL Treatment at ASH Meeting - StockTitan
United Rentals (URI-N) QuotePress Release - The Globe and Mail
Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy Recommendation - MSN
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Increased to Strong-Buy at Brookline Capital Management - MarketBeat
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics - Inkl
Pork Cutout (KMV25) Quote - The Globe and Mail
Nasdaq-100 Ex-Tech Sector Index (NDXX) QuotePress Release - The Globe and Mail
TSX 60 ESG Index (TSXE) QuotePress Release - The Globe and Mail
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
Corn Falling to Start Midweek Trade - The Globe and Mail
Robusta Coffee 10-T (RMK21) Quote - The Globe and Mail
Amer Superconductor (AMSC-Q) QuotePress Release - The Globe and Mail
Caligan Partners LP Has $15.72 Million Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference - The Manila Times
Y-mAbs Therapeutics to Present at Citi's 2024 Global Healthcare Conference | YMAB Stock News - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Royal Bank of Canada (RY-T) QuotePress Release - The Globe and Mail
S&P 500 Energy [Sector] (SREN) QuotePress Release - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Robusta Coffee 10-T (RMU21) Quote - The Globe and Mail
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript - MSN
Oppenheimer Begins Coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs started at outperform at Oppenheimer on pre-targeted radiotherapies - MSN
Oppenheimer Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Outperform Recommendation - MSN
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26% - Simply Wall St
Brain Cancer Treatment Market Growth Overview Future - openPR
Y-mAbs Therapeutics (NASDAQ:YMAB) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock - Benzinga
Institutional investors in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) lost 25% last week but have reaped the benefits of longer-term growth - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives Buy Rating from HC Wainwright - MarketBeat
Trading (YMAB) With Integrated Risk Controls - Stock Traders Daily
MSCI EMI Index (DEZ20) Quote - The Globe and Mail
YMAB FY2024 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Asia Deal Watch: Apollo Takes A Shine To Chinese Biotech’s Cardiometabolic Candidate - Scrip
Cantor Fitzgerald Issues Positive Outlook for YMAB Earnings - MarketBeat
Investors might be losing patience for Y-mAbs Therapeutics' (NASDAQ:YMAB) increasing losses, as stock sheds 13% over the past week - Simply Wall St
Sun Life Financial Inc (SLF-T) QuotePress Release - The Globe and Mail
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Sangamo Therapeutics's Earnings Outlook - Benzinga
Y-mAbs Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsY-mAbs Therapeutics, a biopharmaceutical company focusing on innovative radioimmunotherapy and antibody-based products for cancer treatment, rec - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down After Earnings Miss - Defense World
Earnings call: Y-mAbs Therapeutics reports Q3 2024 financials - Investing.com India
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates - MSN
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):